#USA #Palo Alto #GenBio AI #Digital Organism #Ziv Bar-Joseph

GenBio AI Strengthens Leadership with Ziv Bar-Joseph

In a significant move for the biotechnology landscape, GenBio AI has proudly announced the appointment of Dr. Ziv Bar-Joseph as its Co-Founder and Chief Scientific Officer. Dr. Bar-Joseph will spearhead the integration of GenBio AI's advanced multiscale foundational models, enhancing the company's mission to impact drug discovery and medical applications profoundly.

With a background rich in machine learning and computational sciences, Dr. Bar-Joseph brings a wealth of knowledge acquired through his previous role at Sanofi, a global leader in pharmaceuticals. His experience there as VP and Head of RD Data and Computational Sciences, where he effectively led teams dedicated to machine learning and data science, will be invaluable in his new role at GenBio AI. Moreover, he holds a prestigious position as the FORE Systems Professor of Computer Science at Carnegie Mellon University (CMU), specializing in biological systems modeling.

Dr. Bar-Joseph is recognized for his significant contributions to computational biology, including being awarded the Overton Prize in 2012. His expertise is expected to play a crucial role in driving the innovative integration of artificial intelligence in biological research at GenBio AI. In his own words, he expressed, "GenBio AI is building a world-class research environment to develop the first AI-driven Digital Organism (AIDO), and I'm excited to be part of the team advancing AI-driven biology."

GenBio AI's vision extends far beyond traditional boundaries, aiming to create an innovative model that reshapes our understanding of biology. The company is focused on revolutionizing biomedicine by working towards a detailed understanding of cellular, tissue, and organ biology. Its state-of-the-art multiscale foundation models are set to redefine the landscape from basic research to translational medicine and drug discovery.

Last year, GenBio AI showcased its groundbreaking research at the 38th Annual Conference on Neural Information Processing Systems (NeurIPS), presenting six technical papers on creating the first-ever Digital Organism. This landmark event highlights GenBio AI's dedication to being at the forefront of scientific discovery and innovation.

With operational bases in Palo Alto, Abu Dhabi, and Paris, GenBio AI is strategically positioned to transform the dialogue around biological research. As the field moves towards more integrated approaches to understanding life at a molecular level, the company's pioneering work could pave the way for unprecedented advancements in medical research and therapies that improve human health.

The breadth of applications for GenBio AI's research spans drug discovery, where their innovative modeling can expedite the development of new therapies, and even delve into systems biology, fundamentally changing how we perceive and manipulate biological systems.

Eric Xing, Co-Founder and Chief Scientist of GenBio AI, voiced his excitement for Dr. Bar-Joseph's addition to the team, emphasizing his unparalleled contributions to computational biology. Xing remarked, "Ziv is a highly accomplished colleague from CMU, and his leadership will be instrumental in shaping GenBio AI's research and development directions. We are thrilled to have him on board as we push the frontiers of scientific discovery."

As the company embarks on this exciting journey with Dr. Bar-Joseph leading the charge, the future looks bright for GenBio AI. The path to creating revolutionary AI-driven biological models appears promising, marking a new chapter in the ongoing pursuit of enhanced medical understanding and innovation.

To learn more about opportunities at GenBio AI, visit their careers page at genbio.ai/careers.